口服幽门螺杆菌全菌灭活疫苗联合多重突变霍乱毒素的临床前免疫原性与保护效力
该研究将甲醛灭活的幽门螺杆菌全菌疫苗(WCV)与多重突变霍乱毒素(mmCT)佐剂联合经胃免疫小鼠,结果与WCV联合霍乱毒素(CT)类似,使小鼠胃内幽门螺杆菌定植减少50–125倍,并伴随血清IgG和肠黏膜IgA抗体应答及T细胞、IFNγ和IL-17A细胞因子应答增强。数据还支持该疫苗可在生物反应器中培养,并对来自不同大陆患者的多株致病性幽门螺杆菌有效。结果值得在人体中开展免疫研究以评估其安全性、免疫原性和效力。
要点
- WCV联合mmCT经胃免疫小鼠,胃内幽门螺杆菌定植减少50–125倍。
- 免疫后血清IgG和肠黏膜IgA抗幽门螺杆菌抗体应答均升高。
- 伴随较强的T细胞及IFNγ、IL-17A细胞因子应答。
核心结论
- WCV联合mmCT经胃免疫小鼠可诱导与WCV联合CT相似的免疫保护,使胃内幽门螺杆菌定植减少50–125倍。
- 结果值得在人体中开展免疫研究以评估该疫苗候选的安全性、免疫原性和效力。
研究设计与样本
- 临床前小鼠研究:将甲醛灭活的幽门螺杆菌全菌疫苗(WCV)与多重突变霍乱毒素(mmCT)佐剂混合,经胃内免疫小鼠。
主要发现
- WCV联合mmCT经胃免疫小鼠,胃内幽门螺杆菌定植减少50–125倍,与WCV联合CT免疫类似。
- 免疫后血清IgG和肠黏膜IgA抗幽门螺杆菌抗体应答均升高。
- 伴随较强的T细胞及IFNγ和IL-17A细胞因子应答。
- 数据支持该疫苗可在生物反应器中培养,并对来自不同大陆患者的多株致病性幽门螺杆菌有效。
局限性
- 结果值得在人体中开展免疫研究以评估该疫苗候选的安全性、免疫原性和效力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mucosal vaccines against Helicobacter pylori consisting of either whole cell bacteria or recombinant antigens can induce immune protection against challenge in mice only when co-administrated with a strong mucosal adjuvant such as cholera toxin (CT) or Escherichia coli heat labile enterotoxin (LT). The strong enterotoxicity of these adjuvants however preclude their use in human vaccines. The recently developed multiple mutant CT (mmCT) is a strong, yet practically non-toxic novel mucosal adjuvant which here was admixed with a formalin-inactivated H. pylori whole cell vaccine (WCV) as a potential vaccine candidate against H. pylori infection. We report that intragastric immunizations with H. pylori WCV together with mmCT, similar to immunization with WCV together with CT, resulted in 50-125-fold reduction in colonization of H. pylori in the stomach of mice associated with rises in both serum IgG and intestinal-mucosal IgA anti-H. pylori antibody responses and strong T cell and IFNγ and IL-17A cytokine responses. Data presented in this study also supports that the proposed vaccine can be grown in a bioreactor and would be effective against infection caused by a multitude of pathogenic H. pylori strains isolated from patients from various continents. The results warrant immunization studies in humans to evaluate the safety, immunogenicity and efficacy of the proposed H. pylori WCV and mmCT.
引用
- Holmgren J, Nordqvist S, Blomquist M, et al. Preclinical immunogenicity and protective efficacy of an oral Helicobacter pylori inactivated whole cell vaccine and multiple mutant cholera toxin: A novel and non-toxic mucosal adjuvant. Vaccine. 2018. PMID: 30119923. doi:10.1016/j.vaccine.2018.07.073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。